A meta-analysis of hemoglobin target for anemia of patients with chronic kidney disease

VernacularTitle:血红蛋白靶目标值对慢性肾脏病患者生存影响的荟萃分析
Author: Jing ZHOU ; Weijie YUAN
Publication Type:Journal Article
Keywords: Hemoglobin; Anemia; Chronic kidney disease; Meta-analysis; Randomized controlled trials
From: Chinese Journal of Nephrology 2012;(10):775-779
CountryChina
Language:Chinese
Abstract: Objective To explore the role of hemoglobin (Hb) level in mortality and morbidity of chronic kidney disease (CKD)patients,aiming to give some evidence for therapy of anemia.Methods Randomized,clinical trials (RCTs) were identified by searching Medline,Embase and the Cochrane library.All the analyses were performed using the Revman software available free from the Cochrane collaboration.Results Twenty-three trials involving 10 204 patients were identified.Overall,the high Hb target was associated with increased risk of all-cause mortality (RR=1.10,95％ CI 1.00 to 1.21),hypertension (RR=1.40,95％ CI 1.12 to 1.75),stroke and hospitalization (RR=1.07,95％ CI 1.00 to 1.14) compared with low Hb target (P＜0.05).No significant difference was found in the risks of non-fatal mycardial infarction (RR=1.13,95％ CI 0.79 to 1.62) and renal replacement therapy (RR =1.00,95％ CI 0.85 to 1.18).Conclusions Targeting low Hb target is beneficial to CKD patients based on reduced risk of hypertension,hospitalization,stroke and all-cause mortality.However,no significant difference is found in non-fatal mycardial infarction and renal replacement therapy.